Careers Contact Us

Diabetes

Areas of Partnership Interest

  • Amelioration of insulin resistance
  • Improvement in pancreatic beta cell function/survival
  • Non-invasive approaches to measuring islet cell mass/survival
  • Identification of patients with high cardiovascular risk (that improves on risk assessment by standard phenotype scores like Framingham and UKPDS scores)
  • Reduction of cardiovascular risk factors
  • Identification of subjects at higher risk of diabetes disease progression (e.g., accelerated loss of beta cell function)
  • Surrogate measure of insulin sensitivity with high correlation to gold standard of euglycemic clamp
  • Identification of patients at higher risk of developing diabetic complications
  • Surrogate measure of early impact on diabetic complications

Areas of Less Interest

  • Continuous monitoring technology (no interest in development)

Bob Knowles

Stefanie Hansen
Submit your idea

Text SizeAAA

"Pfizer is committed to flexible, transparent and mutually beneficial long-term relationships with its partners. By joining forces, we can bring quality therapies to patients worldwide. Let's work together for a healthier world."

—Bill Ringo, Senior Vice President,
Worldwide Business Development
Strategy & Innovation